Multiple primary melanomas among 16,570 patients with melanoma diagnosed at Kaiser Permanente Northern California, 1996 to 2011 - 14/09/15
, Alan C. Geller, RN, MPH b, E. Margaret Warton, MPH a, Joan Schwalbe, MS a, Maryam M. Asgari, MD, MPH a, cAbstract |
Background |
Published rates of cutaneous multiple primary melanoma (MPM) vary widely.
Objective |
We examined incidence of and risk factors associated with MPMs among Kaiser Permanente Northern California members.
Methods |
We estimated MPM incidence among 16,570 patients with melanoma from 1996 through 2011. We compared characteristics between patients with MPMs and single primary melanomas and estimated crude and adjusted hazard ratios of MPMs using Cox models.
Results |
In all, 15,448 patients had a single melanoma and 1122 had MPMs. Patients with MPMs were older and more often male, non-Hispanic white, and partnered. Subsequent primary melanomas were diagnosed after a mean of 3.83 (SD 3.61, median 2.82) years and were more likely in situ and thinner than initial tumors. The risk of a subsequent melanoma decreased from 2% in the first year after diagnosis to a stable approximately 1% rate through 15 years of follow-up.
Limitations |
We lacked data on some known melanoma risk factors and had small numbers of non-white patients and certain tumor subtypes.
Conclusions |
The risk of MPMs, although highest in the first year after diagnosis, remains stable thereafter. Those at highest risk of MPMs are older, male, white, and partnered. Clinicians should be aware of the rate of MPMs and recognize high-risk subgroups.
Le texte complet de cet article est disponible en PDF.Key words : incidence, melanoma, multiple primary melanoma, risk, screening, skin cancer
Abbreviations used : aHR, CI, ICD-O-3, KPNC, MPM, NCCR, SEER, SPM
Plan
| Dr Asgari is currently affiliated with the Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. |
|
| Funded by Kaiser Permanente Community Benefit Grant. |
|
| Disclosure: Dr Asgari received institutional research funding from Pfizer and Valeant that is not relevant to this manuscript. Dr Moore, Mr Geller, Ms Warton, and Ms Schwalbe have no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
Vol 73 - N° 4
P. 630-636 - octobre 2015 Retour au numéro
Article précédent
- Dermoscopic changes in melanocytic nevi in patients receiving immunosuppressive and biologic treatments: Results of a prospective case-control study
- Gamze Koseoglu, Bengu Nisa Akay, Orhan Kucuksahin, Cengizhan Erdem
- Detection of mitotic figures in thin melanomas—Immunohistochemistry does not replace the careful search for mitotic figures in hematoxylin-eosin stain
- Karl Ottmann, Michael Tronnier, Christina Mitteldorf
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?